复星医药(02196)向专业投资者公开发行科技创新公司债券获中国证监会注册批复

Core Viewpoint - Fosun Pharma has received approval from the China Securities Regulatory Commission (CSRC) to publicly issue technology innovation corporate bonds with a total face value of up to 6 billion RMB [1] Group 1: Regulatory Approval - The CSRC issued a reply approving Fosun Pharma's application for the registration of the public issuance of technology innovation corporate bonds [1] - The approval is valid for 24 months from the date of registration [1] Group 2: Bond Issuance Details - The company can issue the technology innovation corporate bonds in tranches within the validity period based on funding needs and market conditions [1] - Fosun Pharma will comply with relevant laws, regulations, and the requirements of the approval during the issuance process [1]